Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGEN NASDAQ:TARA NASDAQ:TRDA NYSEAMERICAN:XTNT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGENCompugen$2.10-5.4%$2.61$1.29▼$3.23$209.91M2.74591,745 shs242,438 shsTARAProtara Therapeutics$4.16-5.7%$5.04$2.77▼$7.82$247.86M1.45743,089 shs440,529 shsTRDAEntrada Therapeutics$6.37-9.0%$10.45$4.93▼$16.45$271.74M-0.26485,332 shs195,030 shsXTNTXtant Medical$0.46-0.9%$0.50$0.44▼$0.95$64.54M-0.16162,550 shs62,228 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGENCompugen+1.37%-20.14%-18.38%+6.73%+29.82%TARAProtara Therapeutics+4.50%-7.16%-18.48%-25.25%+36.96%TRDAEntrada Therapeutics+6.38%+2.64%-55.56%-44.36%-11.73%XTNTXtant Medical0.00%-2.11%-20.67%-25.79%-32.54%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGENCompugen$2.10-5.4%$2.61$1.29▼$3.23$209.91M2.74591,745 shs242,438 shsTARAProtara Therapeutics$4.16-5.7%$5.04$2.77▼$7.82$247.86M1.45743,089 shs440,529 shsTRDAEntrada Therapeutics$6.37-9.0%$10.45$4.93▼$16.45$271.74M-0.26485,332 shs195,030 shsXTNTXtant Medical$0.46-0.9%$0.50$0.44▼$0.95$64.54M-0.16162,550 shs62,228 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGENCompugen+1.37%-20.14%-18.38%+6.73%+29.82%TARAProtara Therapeutics+4.50%-7.16%-18.48%-25.25%+36.96%TRDAEntrada Therapeutics+6.38%+2.64%-55.56%-44.36%-11.73%XTNTXtant Medical0.00%-2.11%-20.67%-25.79%-32.54%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGENCompugen 2.80Moderate Buy$5.00138.10% UpsideTARAProtara Therapeutics 2.75Moderate Buy$26.25531.01% UpsideTRDAEntrada Therapeutics 2.50Moderate Buy$18.25186.50% UpsideXTNTXtant Medical 3.00Buy$1.00119.35% UpsideCurrent Analyst Ratings BreakdownLatest XTNT, TARA, CGEN, and TRDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2026CGENCompugen Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$13.00 ➝ $5.005/20/2026TARAProtara Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$25.00 ➝ $28.005/20/2026TARAProtara Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/20/2026TARAProtara Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/20/2026TARAProtara Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/14/2026TARAProtara Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$27.00 ➝ $26.005/13/2026XTNTXtant Medical BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$1.005/8/2026TRDAEntrada Therapeutics Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$10.005/8/2026TRDAEntrada Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral4/29/2026TARAProtara Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$23.00 ➝ $27.004/21/2026TARAProtara Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGENCompugen$72.76M2.73$0.35 per share5.94$1.09 per share1.93TARAProtara TherapeuticsN/AN/AN/AN/A$3.80 per shareN/ATRDAEntrada Therapeutics$25.42M9.73N/AN/A$8.01 per share0.80XTNTXtant Medical$133.93M0.48$0.07 per share6.32$0.36 per share1.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGENCompugen$35.34M$0.375.68N/AN/A47.97%47.72%27.51%8/5/2026 (Estimated)TARAProtara Therapeutics-$57.44M-$1.34N/AN/AN/AN/A-38.70%-36.02%7/30/2026 (Estimated)TRDAEntrada Therapeutics-$143.75M-$3.99N/AN/AN/A-2,895.05%-51.22%-42.20%8/5/2026 (Estimated)XTNTXtant Medical$4.97M-$0.1345.64N/AN/A1.50%3.68%1.91%7/30/2026 (Estimated)Latest XTNT, TARA, CGEN, and TRDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/18/2026Q1 2026CGENCompugen-$0.07-$0.08-$0.01-$0.08$1.57 million$2.18 million5/13/2026Q1 2026TARAProtara Therapeutics-$0.36-$0.31+$0.05-$0.31N/AN/A5/13/2026Q1 2026XTNTXtant Medical-$0.0150-$0.02-$0.0050-$0.02$20.16 million$20.88 million5/7/2026Q1 2026TRDAEntrada Therapeutics-$1.06-$0.95+$0.11-$0.95$2.92 million$0.88 million3/31/2026Q4 2025XTNTXtant Medical-$0.0049$0.0263+$0.0312N/A$30.75 million$32.36 million3/10/2026Q4 2025TARAProtara Therapeutics-$0.34-$0.37-$0.03-$0.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCGENCompugenN/AN/AN/AN/AN/ATARAProtara TherapeuticsN/AN/AN/AN/AN/ATRDAEntrada TherapeuticsN/AN/AN/AN/AN/AXTNTXtant MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGENCompugenN/A6.236.23TARAProtara TherapeuticsN/A15.6915.69TRDAEntrada TherapeuticsN/A13.9013.90XTNTXtant Medical0.173.341.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGENCompugen12.22%TARAProtara Therapeutics38.13%TRDAEntrada Therapeutics86.39%XTNTXtant Medical69.33%Insider OwnershipCompanyInsider OwnershipCGENCompugen9.50%TARAProtara Therapeutics7.60%TRDAEntrada Therapeutics9.49%XTNTXtant Medical10.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGENCompugen7094.55 million85.57 millionOptionableTARAProtara Therapeutics3056.20 million51.93 millionOptionableTRDAEntrada Therapeutics11038.82 million35.14 millionOptionableXTNTXtant Medical120140.26 million125.68 millionNot OptionableXTNT, TARA, CGEN, and TRDA HeadlinesRecent News About These CompaniesXtant Medical Holdings Inc (XTNT) Q1 2026 Earnings Call Highlights: Navigating Challenges and ...May 15, 2026 | finance.yahoo.comXtant Medical Q1 Earnings Call HighlightsMay 15, 2026 | marketbeat.comXtant Medical Holdings, Inc.May 15, 2026 | edition.cnn.comXtant Medical Holdings, Inc. Q1 2026 Earnings Call SummaryMay 15, 2026 | finance.yahoo.comXtant Medical Holdings, Inc. (AMEX:XTNT) Q1 2026 Earnings Call TranscriptMay 14, 2026 | insidermonkey.comXtant Medical Hldgs Q1 2026 Earnings Call TranscriptMay 13, 2026 | finance.yahoo.comXtant Medical Holdings, Inc. (XTNT) Q1 2026 Earnings Call TranscriptMay 13, 2026 | seekingalpha.comXtant Medical Holdings, Inc.: Xtant Medical Reports First Quarter 2026 Financial ResultsMay 13, 2026 | finanznachrichten.deXtant Medical Reports First Quarter 2026 Financial ResultsMay 13, 2026 | prnewswire.comXtant Medical to Announce First Quarter 2026 Financial Results on May 13, 2026May 7, 2026 | prnewswire.comXtant Medical Expands Trivium™ Portfolio with the Commercial Launch of Trivium™ ShapedMay 6, 2026 | prnewswire.comXtant Medical Holdings (XTNT) price target increased by 12.12% to 1.26April 28, 2026 | msn.comXtant Medical and Dilon Technologies Announce Exclusive U.S. Distribution Agreement for Dilon's HEMOBLAST® Bellows ProductApril 13, 2026 | prnewswire.comXtant Medical Holdings (XTNT) price target decreased by 18.52% to 1.12April 10, 2026 | msn.comXtant Medical and Montana Governor's Office of Community Service Announce Support for "Threshold of Life" MemorialApril 9, 2026 | prnewswire.comXtant Medical Holdings, Inc. (AMEX:XTNT) Q4 2025 Earnings Call TranscriptApril 1, 2026 | insidermonkey.comXtant outlines $95M-$99M 2026 revenue outlook as Companion Spine divestiture and Q-code license revenue roll offMarch 31, 2026 | msn.comXtant Medical shares drop nearly 5% as weak 2026 outlook overshadows Q4 beatMarch 31, 2026 | msn.comXtant Medical Holdings Inc (XTNT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...March 31, 2026 | finance.yahoo.comXtant Medical Holdings, Inc. (XTNT) Q4 2025 Earnings Call TranscriptMarch 31, 2026 | seekingalpha.comXtant Medical Reports Fourth Quarter and Full-Year 2025 Financial ResultsMarch 31, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXTNT, TARA, CGEN, and TRDA Company DescriptionsCompugen NASDAQ:CGEN$2.10 -0.12 (-5.41%) Closing price 04:00 PM EasternExtended Trading$2.15 +0.05 (+2.57%) As of 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.Protara Therapeutics NASDAQ:TARA$4.16 -0.25 (-5.67%) Closing price 04:00 PM EasternExtended Trading$4.16 +0.00 (+0.12%) As of 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.Entrada Therapeutics NASDAQ:TRDA$6.37 -0.63 (-9.00%) Closing price 04:00 PM EasternExtended Trading$5.25 -1.12 (-17.65%) As of 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.Xtant Medical NYSEAMERICAN:XTNT$0.46 0.00 (-0.91%) As of 04:10 PM EasternXtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers Certex spinal fixation, Spider cervical plating, Streamline OCT, CervAlign, Axle interspinous fusion, Xpress minimally invasive pedicle screw, Fortex pedicle screw, Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation systems, and Silex sacroiliac joint fusion systems. Further, it provides Calix for cervical and thoracolumbar applications, as well as Irix-C Cervical Integrated Fusion, Irix-A Lumbar Integrated Fusion, Fortilink, and Irix-A Lumbar integrated fusion systems; Coflex device for lumbar spinal stenosis; and CoFix implant for back and disc pain. The company is headquartered in Belgrade, Montana. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
